Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders

Best Practice and Research: Clinical Rheumatology

Volumn 22, Issue 1, 2008, Pages 101-111

  Ralston, Stuart H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

genetic; osteoprotegerin; Paget's disease; RANK; VCP

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; HYDROXYPROLINE; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR RECEPTOR; VALOSIN CONTAINING PROTEIN;

BONE RADIOGRAPHY; BONE TURNOVER; CLINICAL FEATURE; CONGENITAL BONE DISEASE; DRUG EFFICACY; FAMILIAL EXPANSILE OSTEOLYSIS; FLUID THERAPY; FRONTOTEMPORAL DEMENTIA; GENE DELETION; GENE MUTATION; HUMAN; HYPERPHOSPHATASEMIA; INCLUSION BODY MYOSITIS; NONHUMAN; OSTEOCLAST; PAGET BONE DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AGE OF ONSET; DEMENTIA; HUMANS; MYOSITIS, INCLUSION BODY; OSTEITIS DEFORMANS; OSTEOLYSIS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 40149109317     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.11.005     Document Type: Review

References (54)

1. Kanis J.A. Pathophysiology and treatment of Paget's disease of bone. 2nd edn (1998), Martin Dunitz, London pp. 1-303
2. Sofaer J.A., Holloway S.M., and Emery A.E. A family study of Paget's disease of bone. Journal of Epidemiology and Community Health 37 (1983) 226-231
3. Siris E.S., Ottman R., Flaster E., and Kelsey J.L. Familial aggregation of Paget's disease of bone. Journal of Bone and Mineral Research 6 (1991) 495-500
4. Hocking L., Slee F., Cundy T., et al. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone 26 (2000) 577-580
5. Osterberg P.H., Wallace R.G., Adams D.A., et al. Familial expansile osteolysis. A new dysplasia. The Journal of Bone and Joint Surgery. British Volume 70 (1988) 255-260
6. Whyte M.P., Mills B.G., Reinus W.R., et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. Journal of Bone and Mineral Research 15 (2000) 2330-2344
7. Nakatsuka K., Nishizawa Y., and Ralston S.H. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. Journal of Bone and Mineral Research 18 (2003) 1381-1385
8. Whyte M.P., Obrecht S.E., Finnegan P.M., et al. Osteoprotegerin deficiency and juvenile Paget's disease. The New England Journal of Medicine 347 (2002) 175-184
9. Kovach M.J., Waggoner B., Leal S.M., et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Molecular Genetics and Metabolism 74 (2001) 458-475
10. Wallace R.G., Barr R.J., Osterberg P.H., and Mollan R.A. Familial expansile osteolysis. Clinical Orthopaedics and Related Research 248 (1989) 265-277
11. Hughes A.E., Shearman A.M., Weber J.L., et al. Genetic linkage of familial expansile osteolysis to chromosome 18q. Human Molecular Genetics 3 (1994) 359-361
12. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
13. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes & Development 13 (1999) 2412-2424
14. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 1566-1571
15. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
16. Hughes A.E., Ralston S.H., Marken J., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genetics 24 (2000) 45-48
17. Johnson-Pais T.L., Singer F.R., Bone H.G., et al. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. Journal of Bone and Mineral Research 18 (2003) 376-380
18. Palenzuela L., Vives-Bauza C., Fernandez-Cadenas I., et al. Familial expansile osteolysis in a large Spanish kindred resulting from an insertion mutation in the TNFRSF11A gene. Journal of Medical Genetics 39 (2002) E67
19. Whyte M.P., Reinus W.R., Podgornik M.N., and Mills B.G. Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred. Medicine 81 (2002) 101-121
20. Reddy S.V., Singer F.R., Mallette L., and Roodman G.D. Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. Journal of Bone and Mineral Research 11 (1996) 1602-1607
21. Whyte M.P., and Hughes A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. Journal of Bone and Mineral Research 17 (2002) 26-29
22. Albagha O.M.E., Rojas J., van't Hof R.J., et al. A mouse model of early onset Paget's disease of bone caused by an insertion mutation affecting the RANK signal peptide. Calcified Tissue International 80 (2007) S34
23. Golob D.S., McAlister W.H., Mills B.G., et al. Juvenile Paget disease: life-long features of a mildly affected young woman. Journal of Bone and Mineral Research 11 (1996) 132-142
24. Janssens K., de Vernejoul M.C., de Freitas F., et al. An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. Bone 36 (2005) 542-548
25. Cundy T., Hegde M., Naot D., et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Human Molecular Genetics 11 (2002) 2119-2127
26. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
27. Chong B., Hegde M., Fawkner M., et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. Journal of Bone and Mineral Research 18 (2003) 2095-2104
28. Wuyts W., Van Wesenbeeck L., Morales-Piga A., et al. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 28 (2001) 104-107
29. Daroszewska A., Hocking L.J., McGuigan F.E.A., et al. Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. Journal of Bone and Mineral Research 19 (2004) 1506-1511
30. Beyens G., Daroszewska A., De Freitas F., et al. Identification of sex specific effects of TNFRSF11B polymorphisms on the risk of Paget's disease of bone. Calcified Tissue International 80 (2007) S42
31. Greenberg P.B., Doyle F.H., Fisher M.T., et al. Treatment of Paget's disease of bone with synthetic human calcitonin: biochemical and roentgenologic changes. The American Journal of Medicine 56 (1974) 867-870
32. Doyle F.H., Woodhouse N.J., Glen A.C., et al. Healing of the bones in juvenile Paget's disease treated by human calcitonin. The British Journal of Radiology 47 (1974) 9-15
33. Spindler A., Berman A., Mautalen C., et al. Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature. The Journal of Rheumatology 19 (1992) 642-645
34. Tau C., Mautalen C., Casco C., et al. Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy. Bone 35 (2004) 210-216
35. Cundy T., Wheadon L., and King A. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. Journal of Bone and Mineral Research 19 (2004) 703-711
36. Whyte M.P., Wenkert D., Clements K.L., et al. Bisphosphonate-induced osteopetrosis. The New England Journal of Medicine 349 (2003) 457-463
37. Cundy T., Davidson J., Rutland M.D., et al. Recombinant osteoprotegerin for juvenile Paget's disease. The New England Journal of Medicine 353 (2005) 918-923
38. Kimonis V.E., Kovach M.J., Waggoner B., et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genetics in Medicine 2 (2000) 232-241
39. Caughey J.E., Wynne J.F., and Jefferson N. Dystrophia myotonica associated with familial Paget's disease (osteitis deformans) with sarcomata. The Journal of Bone and Joint Surgery. British Volume 39-B (1957) 316-325
40. McBride T.I. Paget's disease and muscular dystrophy. Report of an unusual association in one family. Scottish Medical Journal 11 (1966) 238-243
41. Tucker Jr. W.S., Hubbard W.H., Stryker T.D., et al. A new familial disorder of combined lower motor neuron degeneration and skeletal disorganization. Transactions of the Association of American Physicians 95 (1982) 126-134
42. Watts G.D., Wymer J., Kovach M.J., et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics 36 (2004) 377-381
43. Wang Q., Song C., and Li C.C. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. Journal of Structural Biology 146 (2004) 44-57
44. Frohlich K.U., Fries H.W., Rudiger M., et al. Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression. The Journal of Cell Biology 114 (1991) 443-453
45. Hartmann-Petersen R., Wallace M., Hoffman K., et al. The Ubx2 and Ubx3 cofactors direct Cdc48 activity to proteolytic and nonproteolytic ubiquitin-dependent processes. Current Biology 14 (2004) 824-828
46. Yen H.C., Gordon C., and Chang E.C. Schizosaccharomyces pombe Int6 and Ras homologs regulate cell division and mitotic fidelity via the proteasome. Cell 112 (2003) 207-217
47. Richly H., Rape M., Braun S., et al. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 120 (2005) 73-84
48. Rape M., Hoppe T., Gorr I., et al. Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone. Cell 107 (2001) 667-677
49. Zhong X., Shen Y., Ballar P., et al. AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. The Journal of Biological Chemistry 279 (2004) 45676-45684
50. Weihl C.C., Miller S.E., Hanson P.I., and Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Human Molecular Genetics 16 (2007) 919-928
51. Muller J.M., Deinhardt K., Rosewell I., et al. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochemical and Biophysical Research Communications 354 (2007) 459-465
52. Weihl C.C., Dalal S., Pestronk A., and Hanson P.I. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Human Molecular Genetics 15 (2006) 189-199
53. Lucas G.J., Mehta S.G., Hocking L.J., et al. Evaluation of the role of valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone. Bone 38 (2006) 280-285
54. Selby P.L., Davie M.W., Ralston S.H., and Stone M.D. Guidelines on the management of Paget's disease of bone. Bone 31 (2002) 366-373